Key result
Angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure, particularly in ocular hypertensive eyes, suggesting the RAS regulates IOP.
Why the study?
Do angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure?
Do angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure?
This review suggests that medications targeting the renin-angiotensin system, commonly used for blood pressure control, may also lower intra-ocular pressure.
May support RAS inhibition for IOP control in ocular hypertension; leaves open whether this warrants dedicated glaucoma trials before practice change.
The renin-angiotensin-aldosterone system is known to play an essential role in controlling sodium balance and body fluid volumes, and thus blood pressure. In addition to the circulating system which regulates urgent cardiovascular responses, a tissue-localized renin-angiotensin system (RAS) regulates long-term changes in various organs. Many recognized RAS components have also been identified in the human eye. The highly vasoconstrictive angiotensin II (Ang II) is considered the key peptide in the circulatory RAS. However, the ultimate effect of RAS activation at tissue level is more complex, being based not only on the biological activity of Ang II but also on the activities of other products of angiotensinogen metabolism, often exerting opposite effects to Ang II action. In recent studies, orally administered angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure (IOP), likewise topical application of these compounds, the effect being more prominent in ocular hypertensive eyes. Based on previous findings and our own experimental data, it can strongly be suggested that the RAS not only regulates blood pressure but is also involved in the regulation of IOP.
No takes yet. Share an insight, caveat, or question.
Vaajanen et al. (2008) conducted a review in Ocular hypertension. Angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors was evaluated on Intra-ocular pressure (IOP). Angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure, particularly in ocular hypertensive eyes, suggesting the RAS regulates IOP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: